Market Overview - The Shanghai Composite Index is at 3660.38 points, above the five-day moving average, with a change of 0.35% [1] - The total trading volume of A-shares is 858.514 billion yuan [1] Stocks Breaking the Five-Day Moving Average - A total of 237 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Yutian Guanjia (301173) with a deviation rate of 10.53% and a daily increase of 13.54% [2] - Meiri Hudong (300766) with a deviation rate of 8.80% and a daily increase of 11.81% [2] - Dayang Biological (003017) with a deviation rate of 8.02% and a daily increase of 10.00% [2] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Fenghuo Electronics (000561) with a deviation rate of 7.29% and a daily increase of 9.97% [2] - Shenzhou Taiyue (300002) with a deviation rate of 5.63% and a daily increase of 7.41% [2] - Lain Biological (002166) with a deviation rate of 5.26% and a daily increase of 6.70% [2] Summary of Stocks with Lower Deviation Rates - Stocks with smaller deviation rates that have just crossed the five-day moving average include: - Changchun Gaoxin, Lidasin, and Kaikai Industry [1]

开开实业最新一期业绩显示，截至2025一季报，公司营业总收入2.70亿元、同比增长15.05%，归属净利 润797.84万元，同比减少65.70%，扣非净利润147.50万元，同比增长527.72%，流动比率1.368、速动比 率1.254、资产负债率57.08%。 来源：金融界 金融界消息 截至2025年8月11日收盘，开开实业（600272）报收于14.1元，上涨0.93%，换手率2.7%， 成交量4.33万手，成交金额6083.98万元。 天眼查商业履历信息显示，上海开开实业股份有限公司，成立于1997年，位于上海市，是一家以从事纺 织业为主的企业。企业注册资本24300万人民币，实缴资本24300万人民币。公司法定代表人为庄虔贇。 资金流向方面，今日主力资金净流出1181.13万元，占比成交额19.41%。其中，超大单净流出882.46万 元、占成交额14.5%，大单净流出298.67万元、占成交额4.91%，中单净流出流入40.36万元、占成交额 0.66%，小单净流入1140.77万元、占成交额18.75%。 通过天眼查大数据分析，上海开开实业股份有限公司共对外投资了24家企业，参与招投标项目20 ...

| 股票代码：600272 | 股票简称：开开实业 | | | 编号：2025—050 | | --- | --- | --- | --- | --- | | 900943 | | 开开 | B 股 | | 上海开开实业股份有限公司 关于使用暂时闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海开开实业股份有限公司（以下简称"公司"）从募集资 金理财产品专用结算账户中支取了3,500万元至募集资金专户，该笔资金 将用于补充日常经营所需流动资金。现将相关情况公告如下： 一、募集资金进行现金管理的基本概况 公司于2025年7月21日召开公司第十届董事会第二十六次会议、第十 届监事会第十八次会议，审议通过了《关于使用暂时闲置募集资金进行 现金管理的议案》，公司计划使用不超过人民币15,549.00万元（含本数） 暂时闲置募集资金进行现金管理，使用期限不超过12个月，在上述额度 及决议有效期内，资金可以循环使用，暂时闲置募集资金投资产品到期 后的本金及收益将及时归还至募集资金专户。公司保 ...

Core Viewpoint - Shanghai Kaikai Industrial Co., Ltd. plans to transfer 11.11% equity stake in Nanjing Tianshi Software Technology Co., Ltd. to enhance asset utilization efficiency and focus on core business development [9][12][20] Group 1: Equity Transfer - The company intends to publicly transfer its 11.11% stake in Nanjing Tianshi through the Shanghai United Assets and Equity Exchange, with a minimum transfer price of 1,741.23 million RMB based on a pre-evaluation value of 15,672.62 million RMB as of December 31, 2024 [9][19][20] - The decision to transfer the stake was approved unanimously by the board of directors, with 9 votes in favor and no opposition [3][14] - The transaction does not constitute a related party transaction or a major asset restructuring, and it does not require shareholder approval [10][11][12] Group 2: Internal Loan Authorization - The company authorized an increase in the internal loan limit to its wholly-owned subsidiaries from 12 million RMB to 25 million RMB to support the transformation of its "big health" business strategy [4][5] - The internal loans will have an interest rate not lower than the prevailing loan market quotation rate (LPR) and can be reused [4][5] - This internal loan authorization aims to facilitate the rapid development of the subsidiaries' business without adversely affecting the company's financial health [4][5] Group 3: Company Strategy and Future Outlook - The equity transfer aligns with the company's strategic focus on enhancing investment efficiency and reducing investment risks, thereby optimizing its investment structure [13][20] - Post-transaction, the company will no longer hold any equity in Nanjing Tianshi, allowing it to concentrate resources on its core competencies and the "big health" industry transformation [13][20] - The company emphasizes that the transaction will not negatively impact its future financial status or operational results [21]

Core Points - The company is focusing on divesting low-efficiency assets to enhance resource allocation and improve asset utilization efficiency by transferring 11.11% equity in Nanjing Tianshi Software Technology Co., Ltd. [1] - The board approved an increase in the internal loan limit to support the full subsidiary's transformation in the "big health" industry, raising the total limit to 25 million RMB [2][3] Group 1 - The board meeting was held on August 1, 2025, with all 9 directors present, and the meeting complied with relevant laws and regulations [1] - The decision to transfer equity was made to focus on core business development and improve asset utilization [1] - The internal loan authorization aims to support the subsidiary's funding needs during its transformation in the "big health" sector [2][3] Group 2 - The internal loan will be sourced from the company's own funds and is not expected to negatively impact the company's ongoing operations or financial status [3] - The internal loan interest rate will not be lower than the prevailing loan market quotation rate [2]

Group 1 - The company has announced a postponement of the board and supervisory board elections due to the recent completion of a specific A-share issuance project, ensuring continuity and stability in operations [1] - The current board and supervisory board members will continue to perform their duties until the new elections are completed, in accordance with relevant laws and regulations [1] - The postponement of the elections will not affect the normal operations of the company, and the company will expedite the election process and fulfill disclosure obligations [1] Group 2 - Independent director Chen Yamin has submitted his resignation after serving for six years, in compliance with relevant laws and regulations [2] - Chen Yamin's resignation will take effect only after the election of a new independent director at the shareholders' meeting, and he will continue to fulfill his duties until then [3] - The company expresses gratitude for Chen Yamin's contributions to its governance and development during his tenure [3]

Group 1 - The company announced the approval of a proposal to transfer 11.11% equity stake in Nanjing Tianshi Software Technology Co., Ltd. [1] - The board also approved a proposal to authorize internal loans to the company's wholly-owned subsidiary [1]

Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

开开实业（600272）(600272.SH)公告，公司拟通过上海联合产权交易所以公开挂牌转让的方式将所持 有的南京天石软件技术有限公司(简称"南京天石")11.11%股权进行转让。本次公开挂牌转让底价将不低 于1741.23万元。转让完成后公司将不再持有南京天石股权。 ...

格隆汇8月1日丨开开实业(600272.SH)公布，公司拟通过上海联合产权交易所以公开挂牌转让的方式将 所持有的南京天石软件技术有限公司(以下简称"南京天石")11.11%股权进行转让。经有证券期货业务从 业资格的资产评估机构预评估，以2024年12月31日为基准日，南京天石预评估价为人民币15,672.62万 元，本次公开挂牌转让底价将不低于公司所持有南京天石11.11%股权对应的预评估价值1,741.23万元。 ...